Hengrui Yuanzheng Completes Over RMB 200 Million Series C Financing Led by Zijin Harbor Capital, with Participation from Hengrui Pharmaceuticals and Zhongke Sci-Tech

Investment Circle (ID: pedaily2012) May 17 News: Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd. has completedSeries C Financing Exceeds 200 Million Yuan，Goldport CapitalAs the lead investor in this round, they continued to increase their investment. Other key investors in this round includeHengrui Pharma, Goldport CapitalHengrui Yuanzheng completed its Series A+ and Series B financing rounds in 2020, and in 2021 established its headquarters base in Songjiang, Shanghai, as well as a cell preparation center for the Yangtze River Delta region.

Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd., established in Shanghai in 2015 by Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shenzhen Yuanzheng Cell Medical Technology Co., Ltd., is a leading immunotherapy company in China that focuses on solid tumors and operates in sync with international standards. The company has developed multiple product pipelines for solid tumor patients, including MASCT, TCR-T, and TCR bispecific antibodies. Among these, the MASCT pipeline is the world's first multi-target cell therapy product for solid tumors to have received clinical approval and has now entered Phase II clinical trials. The TCR-T pipeline isolates TCRs with optimal affinity from tumor patients who have benefited from years of MASCT clinical treatment, accumulating extensive TCR data based on Asian HLA types, offering significant advantages over TCR products based on European and American HLA types. The TCR bispecific antibody is a standardized product that can be mass-produced, providing cost and efficiency benefits over customized cell therapy products.

In addition, recently, the first TCR-T product HRYZ-T101 developed by Hengrui Yuanzheng's self-developed ReGET platform has obtained the IND approval from the CDE! This product is the world’s first TCR-T product targeting high-frequency HLA in the Chinese population, with patent authorization in both China and the United States, as well as extensive PCT coverage. It features a novel TCR sequence and is a First-in-class TCR-T cell therapy product for an innovative solid tumor target. The IND approval of this TCR-T product marks an important milestone in Hengrui Yuanzheng's self-developed journey.

HRYZ-T101 Injection is the second IND-approved product from Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd., and also its first TCR-T cell therapy product. TCR-T is a type of TCR gene-modified T-cell technology that enhances the ability of T cells to recognize and kill tumor cells by expressing tumor-specific TCR chains in T cells. Unlike CAR molecules, which can only recognize membrane proteins, TCR molecules are capable of identifying intracellular proteins presented by tumor cells. This feature gives TCR-T technology greater advantages and potential in the treatment of solid tumors and has become a hot topic in the field of immune cell therapy.

Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd. has independently developed a TCR screening technology platform based on reverse gene engineering (Reverse Genetic Engineering of TCR-T, ReGET), which can rapidly and efficiently isolate TCRs with optimal affinity from tumor patients who benefit from immunotherapy. The platform has accumulated a large amount of TCR data based on Asian HLA typing, for use in the development of anti-tumor TCR-T products, offering significant advantages over TCR products based on European and American HLA typing.